Cargando…
Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence
Recurrent Glioblastoma presents a formidable challenge in oncology due to its aggressive nature and limited treatment options. Tumour-Treating Fields (TTFields) Therapy, a novel therapeutic modality, has emerged as a promising approach to address this clinical conundrum. This review synthesizes the...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695547/ http://dx.doi.org/10.1097/MD.0000000000036421 |
_version_ | 1785153589511979008 |
---|---|
author | Olatunji, Gbolahan Aderinto, Nicholas Adefusi, Temiloluwa Kokori, Emmanuel Akinmoju, Olumide Yusuf, Ismaila Olusakin, Tobi Muzammil, Muhammad Ali |
author_facet | Olatunji, Gbolahan Aderinto, Nicholas Adefusi, Temiloluwa Kokori, Emmanuel Akinmoju, Olumide Yusuf, Ismaila Olusakin, Tobi Muzammil, Muhammad Ali |
author_sort | Olatunji, Gbolahan |
collection | PubMed |
description | Recurrent Glioblastoma presents a formidable challenge in oncology due to its aggressive nature and limited treatment options. Tumour-Treating Fields (TTFields) Therapy, a novel therapeutic modality, has emerged as a promising approach to address this clinical conundrum. This review synthesizes the current evidence surrounding the efficacy of TTFields Therapy in the context of recurrent Glioblastoma. Diverse academic databases were explored to identify relevant studies published within the last decade. Strategic keyword selection facilitated the inclusion of studies focusing on TTFields Therapy’s efficacy, treatment outcomes, and patient-specific factors. The review reveals a growing body of evidence suggesting the potential clinical benefits of TTFields Therapy for patients with recurrent Glioblastoma. Studies consistently demonstrate its positive impact on overall survival (OS) and progression-free survival (PFS). The therapy’s safety profile remains favorable, with mild to moderate skin reactions being the most commonly reported adverse events. Our analysis highlights the importance of patient selection criteria, with emerging biomarkers such as PTEN mutation status influencing therapy response. Additionally, investigations into combining TTFields Therapy with other treatments, including surgical interventions and novel approaches, offer promising avenues for enhancing therapeutic outcomes. The synthesis of diverse studies underscores the potential of TTFields Therapy as a valuable addition to the armamentarium against recurrent Glioblastoma. The narrative review comprehensively explains the therapy’s mechanisms, clinical benefits, adverse events, and future directions. The insights gathered herein serve as a foundation for clinicians and researchers striving to optimize treatment strategies for patients facing the challenging landscape of recurrent Glioblastoma. |
format | Online Article Text |
id | pubmed-10695547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-106955472023-12-05 Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence Olatunji, Gbolahan Aderinto, Nicholas Adefusi, Temiloluwa Kokori, Emmanuel Akinmoju, Olumide Yusuf, Ismaila Olusakin, Tobi Muzammil, Muhammad Ali Medicine (Baltimore) 5300 Recurrent Glioblastoma presents a formidable challenge in oncology due to its aggressive nature and limited treatment options. Tumour-Treating Fields (TTFields) Therapy, a novel therapeutic modality, has emerged as a promising approach to address this clinical conundrum. This review synthesizes the current evidence surrounding the efficacy of TTFields Therapy in the context of recurrent Glioblastoma. Diverse academic databases were explored to identify relevant studies published within the last decade. Strategic keyword selection facilitated the inclusion of studies focusing on TTFields Therapy’s efficacy, treatment outcomes, and patient-specific factors. The review reveals a growing body of evidence suggesting the potential clinical benefits of TTFields Therapy for patients with recurrent Glioblastoma. Studies consistently demonstrate its positive impact on overall survival (OS) and progression-free survival (PFS). The therapy’s safety profile remains favorable, with mild to moderate skin reactions being the most commonly reported adverse events. Our analysis highlights the importance of patient selection criteria, with emerging biomarkers such as PTEN mutation status influencing therapy response. Additionally, investigations into combining TTFields Therapy with other treatments, including surgical interventions and novel approaches, offer promising avenues for enhancing therapeutic outcomes. The synthesis of diverse studies underscores the potential of TTFields Therapy as a valuable addition to the armamentarium against recurrent Glioblastoma. The narrative review comprehensively explains the therapy’s mechanisms, clinical benefits, adverse events, and future directions. The insights gathered herein serve as a foundation for clinicians and researchers striving to optimize treatment strategies for patients facing the challenging landscape of recurrent Glioblastoma. Lippincott Williams & Wilkins 2023-12-01 /pmc/articles/PMC10695547/ http://dx.doi.org/10.1097/MD.0000000000036421 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 5300 Olatunji, Gbolahan Aderinto, Nicholas Adefusi, Temiloluwa Kokori, Emmanuel Akinmoju, Olumide Yusuf, Ismaila Olusakin, Tobi Muzammil, Muhammad Ali Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence |
title | Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence |
title_full | Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence |
title_fullStr | Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence |
title_full_unstemmed | Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence |
title_short | Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence |
title_sort | efficacy of tumour-treating fields therapy in recurrent glioblastoma: a narrative review of current evidence |
topic | 5300 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695547/ http://dx.doi.org/10.1097/MD.0000000000036421 |
work_keys_str_mv | AT olatunjigbolahan efficacyoftumourtreatingfieldstherapyinrecurrentglioblastomaanarrativereviewofcurrentevidence AT aderintonicholas efficacyoftumourtreatingfieldstherapyinrecurrentglioblastomaanarrativereviewofcurrentevidence AT adefusitemiloluwa efficacyoftumourtreatingfieldstherapyinrecurrentglioblastomaanarrativereviewofcurrentevidence AT kokoriemmanuel efficacyoftumourtreatingfieldstherapyinrecurrentglioblastomaanarrativereviewofcurrentevidence AT akinmojuolumide efficacyoftumourtreatingfieldstherapyinrecurrentglioblastomaanarrativereviewofcurrentevidence AT yusufismaila efficacyoftumourtreatingfieldstherapyinrecurrentglioblastomaanarrativereviewofcurrentevidence AT olusakintobi efficacyoftumourtreatingfieldstherapyinrecurrentglioblastomaanarrativereviewofcurrentevidence AT muzammilmuhammadali efficacyoftumourtreatingfieldstherapyinrecurrentglioblastomaanarrativereviewofcurrentevidence |